Skip to main content
HRES 1125 116th Congress House

Expressing support for prioritizing racial and ethnic diversity in clinical trials for therapies, diagnostics, and vaccines for COVID-19.

Introduced: September 18, 2020 See on congress.gov
Health Cardiovascular and respiratory healthCommunity life and organizationEmergency medical services and trauma careHealth care coverage and access
More subjectsShow fewer subjects
Health programs administration and fundingImmunology and vaccinationInfectious and parasitic diseasesMedical researchMedical tests and diagnostic methodsMinority healthResearch administration and funding
Sign in to write a letter Sign in to watch
This resolution expired with the 116th Congress
It was not agreed to before the 116th Congress (2019–2020) adjourned, so it is no longer active. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Agreed to (House)
Sep 18, 2020
Introduced in House
Sep 18, 2020
Referred to the House Committee on Energy and Commerce.
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action September 18, 2020

Referred to the House Committee on Energy and Commerce.

 Plain-English summary Congressional Research Service

This resolution expresses the sense of the House of Representatives that federal agencies should take appropriate actions to (1) ensure meaningful engagement of communities of color in the conduct of COVID-19 (i.e., coronavirus disease 2019) research and participation in clinical trials, and (2) improve equitable access to safe and effective vaccines.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Cosponsors 17
All 17 Democratic 13
D
Chu, Judy
California · Sep 30, 2020
Luria, Elaine
· Sep 30, 2020
 D
Castro, Joaquin
Texas · Sep 23, 2020
 D
Barragán, Nanette Diaz
California · Sep 18, 2020
 D
Bera, Ami
California · Sep 18, 2020
 D
Cisneros, Gilbert Ray
California · Sep 18, 2020
 D
Cohen, Steve
Tennessee · Sep 18, 2020
 D
Espaillat, Adriano
New York · Sep 18, 2020
 D
Hayes, Jahana
Connecticut · Sep 18, 2020
JOHNSON, EDDIE
· Sep 18, 2020
 D
McGovern, James P.
Massachusetts · Sep 18, 2020
 D
Meeks, Gregory W.
New York · Sep 18, 2020
 D
Nadler, Jerrold
New York · Sep 18, 2020
 D
Norton, Eleanor Holmes
District of Columbia · Sep 18, 2020
PRICE, DAVID
· Sep 18, 2020
 D
Sewell, Terri A.
Alabama · Sep 18, 2020
Sires, Albio
· Sep 18, 2020
Cite this page click to expand
APA
U.S. Congress. (2026). H. Res. 1125: Expressing support for prioritizing racial and ethnic diversity in clinical trials for therapies, diagnostics, and vaccines for COVID-19.. 116th Congress. Open America. https://openamerica.io/bill/116-HRES-1125/
MLA
"H. Res. 1125: Expressing support for prioritizing racial and ethnic diversity in clinical trials for therapies, diagnostics, and vaccines for COVID-19.." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-HRES-1125/.
Bluebook (legal)
H. Res. 1125, 116th Cong. (2026), https://openamerica.io/bill/116-HRES-1125/.
Markdown link
[H. Res. 1125: Expressing support for prioritizing racial and ethnic diversity in clinical trials for therapies, diagnostics, and vaccines for COVID-19.](https://openamerica.io/bill/116-HRES-1125/)
Report a problem